Peter Martin, MD

Articles

Dr. Martin on the Importance of Designing Clinical Trials for Real-World Utility in MCL

August 16th 2021

Peter Martin, MD, discusses the importance of designing clinical trials for real-world utility in mantle cell lymphoma.

Dr. Martin on the Role of Maintenance Therapy With Rituximab in MCL

July 15th 2021

Peter Martin, MD, discusses the role of maintenance therapy with rituximab in mantle cell lymphoma.

Dr. Martin on the Findings of a Real-World Analysis of Outcomes in MCL

June 23rd 2021

Peter Martin, MD, discusses the findings of a real-world analysis of clinical outcomes in mantle cell lymphoma.

Dr. Martin on the Rationale to Evaluate Real-World Outcomes in MCL

June 16th 2021

Peter Martin, MD, discusses the rationale to evaluate real-world outcomes in mantle cell lymphoma.

Dr. Martin on the Utility of CAR T-Cell Therapy in High-Risk MCL

April 2nd 2021

Peter Martin, MD, discusses selecting treatment for patients with high-risk mantle cell lymphoma.

Dr. Martin on Selecting Among FDA-Approved BTK Inhibitors in MCL

March 19th 2021

Peter Martin, MD, discusses selecting among BTK inhibitors for the treatment of patients with mantle cell lymphoma.

Dr. Martin on Treatment Considerations for MCL

March 17th 2021

Peter Martin, MD, discusses treatment considerations for patients with mantle cell lymphoma.

Dr. Martin on the Importance of Developing Novel Therapies in MCL

March 11th 2021

Peter Martin, MD, discusses the importance of developing novel therapies in mantle cell lymphoma.

Dr. Martin on the Potential Role of LOXO-305 in MCL

March 5th 2021

Peter Martin, MD, discusses the potential role of LOXO-305 in mantle cell lymphoma.

Dr. Martin on Potential Combination Strategies With BTK Inhibitors in MCL

March 1st 2021

Peter Martin, MD, discusses potential combination regimens with BTK inhibitors in mantle cell lymphoma.

Dr. Martin on Potential Drug-Drug Interactions With BTK Inhibitors in MCL

February 26th 2021

Peter Martin, MD, discusses potential drug-drug interactions with BTK inhibitors in relapsed/refractory mantle cell lymphoma.

Dr. Martin on the Frontline Treatment Landscape of MCL

July 13th 2020

Peter Martin, MD, discusses the frontline treatment landscape of mantle cell lymphoma.

Dr. Martin Discusses the Heterogeneity of MCL

September 11th 2019

Peter Martin, MD, associate professor of medicine, chief, the Lymphoma Program, Meyer Cancer Center, Weill Cornell Medicine, discusses the heterogeneity of mantle cell lymphoma (MCL).

Dr. Martin on Ibrutinib/Palbociclib Combo in Ibrutinib-Resistant MCL

August 16th 2019

Peter Martin, MD, discusses a phase I trial examining the ibrutinib plus palbociclib combination in ibrutinib-resistant patients with mantle cell lymphoma.

Dr. Martin on Intensive Therapy for Young Patients with MCL

August 6th 2019

Peter Martin, MD, associate professor of medicine, chief, the Lymphoma Program, Meyer Cancer Center, Weill Cornell Medicine, discusses standard of care for younger patients with mantle cell lymphoma.

Dr. Martin on Trial of Oral Azacitidine Plus R-CHOP in High Risk DLBCL

January 6th 2018

Peter Martin, MD, assistant professor of medicine in the Division of Hematology/Oncology at Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses a trial of the combination of oral azacitidine (CC-486) and R-CHOP in diffuse large B-cell lymphoma (DLBCL).

Dr. Martin on Potential for CAR T-Cell Therapy in MCL Landscape

September 1st 2017

Peter Martin, MD, assistant professor of medicine in the Division of Hematology/Oncology at Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the potential of chimeric antigen receptor (CAR) T-cell therapy in the landscape of mantle cell lymphoma (MCL).

Dr. Martin on Potential of Immunotherapy in MCL Landscape

August 18th 2017

Peter Martin, MD, assistant professor of medicine in the Division of Hematology/Oncology at Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the potential of modern immunotherapies in the landscape of mantle cell lymphoma (MCL).

Dr. Martin on ASCT-Related Toxicities for Patients With MCL

August 8th 2017

Peter Martin, MD, assistant professor of medicine in the Division of Hematology/Oncology at Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the toxicities related to stem cell transplantation for patients with mantle cell lymphoma (MCL).

Dr. Martin on the Role of Transplant in Mantle Cell Lymphoma

May 23rd 2017

Peter Martin, MD, assistant professor of medicine in the Division of Hematology/Oncology at Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the role of transplant in the field of mantle cell lymphoma (MCL).